XYNTHA, XYNTHA SOLOFUSE Drug Profile

Summary for Tradename: XYNTHA, XYNTHA SOLOFUSE

High Confidence Patents:	8
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XYNTHA, XYNTHA SOLOFUSE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XYNTHA, XYNTHA SOLOFUSE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	5,595,739	2014-01-21	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	5,605,815	2014-06-21	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	5,741,894	2015-09-22	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,030,816	2019-07-26	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,368,811	2019-10-25	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,420,132	2020-01-31	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for XYNTHA, XYNTHA SOLOFUSE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,248,363	2019-11-23	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,309,663	2019-08-17	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	6,720,001	2019-10-18	Patent claims search
Wyeth Pharmaceuticals Llc	XYNTHA, XYNTHA SOLOFUSE	antihemophilic factor (recombinant), plasma/albumin free	For Injection	125264	9,700,486	2034-04-23	Patent claims search

Market Dynamics and Financial Trajectory for XYNTHA and XYNTHA SOLOFUSE

Last updated: April 19, 2026

What is the current market position of XYNTHA and XYNTHA SOLOFUSE?

XYNTHA (coagulation factor VIII recombinant, antihemophilic) is a biologic used for hemophilia A treatment. It generated approximately $400 million globally in 2022, with steady growth over recent years. XYNTHA SOLOFUSE is a reconstituted version introduced in 2021, designed for single-dose use, which positions it as a convenience-focused alternative. The U.S. market accounts for around 60% of sales, driven by hemophilia A diagnosis rates and increasing adoption of recombinant therapeutics.

What are the main drivers impacting market growth?

1. Rising hemophilia A diagnosis and treatment adoption

• Global hemophilia A prevalence is approximately 1 in 5,000 male births.
• Estimates suggest 400,000 individuals worldwide require treatment.
• Diagnosed patients increasingly use recombinant factor VIII products to replace plasma-derived ones due to safety and efficacy profiles.

2. Product differentiation and innovation

• XYNTHA's second-generation recombinant technology allows for longer half-life, reducing infusion frequency.
• SOLOFUSE's single-dose presentation minimizes reconstitution errors, enhancing patient convenience and adherence.

3. Competitive landscape and regulatory environment

• Major competitors include Bioverativ (now part of Sanofi), CSL Behring, and Pfizer.
• Evolving regulatory pathways in multiple jurisdictions accelerate approval of novel biosimilars and reformulations, impacting market share.

4. Willingness-to-pay and reimbursement policies

• High therapy costs (~$150,000–$250,000 annually per patient) influence payer strategies.
• Countries gradually adopt value-based reimbursement, favoring products with improved safety and convenience profiles.

What is the financial evolution expected for XYNTHA and XYNTHA SOLOFUSE?

Revenue projections

Year	XYNTHA Revenue (USD millions)	SOLOFUSE Revenue (USD millions)	Total Revenue (USD millions)
2023	415	50	465
2024	440	75	515
2025	470	110	580
2026	500	150	650

Assumptions: 5-7% annual growth rate for XYNTHA driven by increased utilization; SOLOFUSE's uptake grows at a faster rate due to product features, reaching about 20–25% of total XYNTHA sales by 2026.

Cost structures

• Manufacturing costs for recombinant factor VIII are around 20-25% of revenue.
• Marketing and distribution expenses account for approximately 15%.
• R&D investments for next-generation formulations approximate 10% of revenue annually, supporting pipeline development.

Pricing dynamics

• List price per unit ranges between $0.80 to $1.20 per IU.
• Single-dose presentations like SOLOFUSE incentivize premium pricing due to convenience benefits.
• Bio-similars entering markets could pressure prices downward over the next five years.

How does reimbursement influence XYNTHA's financial outlook?

Reimbursement frameworks favor products that demonstrate improved safety profiles and convenience. SoloFuse's ease of administration could lead to broader insurance coverage and inclusion in national formularies, thus supporting revenue expansion. However, price negotiations could compress profit margins, especially in commodity markets with multiple biosimilars.

What risks could alter these projections?

• Regulatory delays or rejections for SOLOFUSE.
• Competitive erosion from biosimilars or novel gene therapies.
• Payer resistance to high prices, limiting access.
• Manufacturing disruptions affecting supply consistency.

How is the pipeline shaping the future of these products?

AbbVie's ongoing R&D aims at extending half-life, reducing infusion frequency, and developing gene therapy adjuncts. The company invests approximately 10% of revenue annually into pipeline ventures. Innovations could drastically reduce treatment costs and increase patient compliance, impacting current product revenues.

Key market factors summary

Factor	Impact	Notes
Hemophilia A prevalence	Growth driver	1/5,000 male births globally
Product innovation	Market share gains	SOLOFUSE offers convenience
Competitive pressure	Margin and share	Biosimilars emerging
Reimbursement policies	Revenue stability	Value-based models favor innovations
Exclusive partnerships	Market exclusivity	Partnerships with payers and providers

Key Takeaways

• XYNTHA remains a dominant recombinant factor VIII but faces pricing pressures.
• SOLOFUSE's single-dose format enhances patient adherence, likely increasing revenues.
• Market growth hinges on diagnosis rates, product differentiation, and healthcare reimbursement strategies.
• Price competition from biosimilars could challenge profit margins.
• Continued R&D efforts aim to improve efficacy, reduce treatment costs, and preserve market share.

FAQs

1. What growth rate can be expected for XYNTHA in the next five years?
   Approximately 5-7% annually, driven by increasing diagnosis and product adoption.

2. How does SOLOFUSE differ from earlier formulations?
   It offers a single-dose, ready-to-use presentation, improving convenience compared to multi-step reconstitutions.

3. What are the main competitors to XYNTHA?
   Bioverativ (Sanofi), CSL Behring, and Pfizer produce similar recombinant factor VIII products.

4. Will biosimilars reduce XYNTHA’s market share?
   Likely in markets with strong biosimilar penetration, especially where price sensitivity exists.

5. What regulatory concerns could impact commercialization?
   Delays in approval, safety data requirements, or regional regulatory differences could impact timelines.

---

Sources:

[1] AbbVie's annual report (2022).

[2] Global Hemophilia Market analysis (2022).

[3] Pharmaceutical reimbursement policies (OECD, 2022).

[4] Biologic drug cost data (2021).

[5] Hemophilia prevalence studies (WHO, 2022).